Trials / Completed
CompletedNCT00246922
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)
A Long-term Study of APTA-2217 in Adult Patients With Bronchial Asthma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years – 71 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with asthma, who completed the 24-week evaluation of study APTA-2217-05. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is the extension of the 24-week study APTA-2217-05 (registered study). The study will provide further long-term safety and efficacy data of roflumilast.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Roflumilast |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2007-01-01
- Completion
- 2007-10-01
- First posted
- 2005-11-01
- Last updated
- 2026-02-18
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00246922. Inclusion in this directory is not an endorsement.